Nanosuspensions of poorly water soluble drugs prepared by top-down technologies

Current Pharmaceutical Design

Volumn 20, Issue 3, 2014, Pages 388-407

  Zhang, Xin ^a   Li, Luk Chiu ^b   Mao, Shirui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b ABBOTT LABORATORIES   (United States)

Author keywords

High pressure homogenization; Media milling; Nanosuspensions; Solidification; Stability; Stabilizer

Indexed keywords

BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; MODELS, CHEMICAL; NANOPARTICLES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SUSPENSIONS; TECHNOLOGY, PHARMACEUTICAL; WATER;

EID: 84894061025     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990401     Document Type: Review

References (184)

1. Das AK, Mandal SC, Banerjee SK, et al. Studies on the hypoglycaemic activity of Punica granatum seed in streptozotocin induced diabetic rats. Phytother Res 2001; 15: 628-9.
2. Lee YJ, Lee YM, Lee CK, et al. Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther 2011; 130: 157-76.
3. Song JS, Lim KM, Kang S, et al. Procoagulant and prothrombotic effects of the herbal medicine, Dipsacus asper and its active ingredient, dipsacus saponin C, on human platelets. J Thromb Haemost 2012; 10: 895-906.
4. C. Lipinski. Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev 2002; 5: 82-5.
5. Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006; 62: 3-16.
6. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev 2011; 63: 427-40.
7. Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008; 364: 64-75.
8. Na GC, Stevens HJ, Jr., Yuan BO, Rajagopalan N. Physical stability of ethyl diatrizoate nanocrystalline suspension in steam sterilization. Pharm Res 1999; 16: 569-74.
9. Müller RH, Möschwitzer J, Bushrab FN. Manufacturing of nanoparticles by milling and homogenization techniques. In: Gupta RB, Kompella, U.B., eds., Nanoparticle Technology for Drug Delivery. Taylor & Francis Group: New York 2006; pp. 21-51.
10. Müller AA. Drug nanocrystals of poorly soluble drugs. In: Nalwa HS, eds., Encyclopedia of Nanoscience and Nanotechnology. Am Scientific Pub 2004; pp. 627-38.
11. Mitri K, Shegokar R, Gohla S, Anselmi C, Muller RH. Lutein nanocrystals as antioxidant formulation for oral and dermal delivery. Int J Pharm 2011; 420: 141-6.
12. Gao Y, Li Z, Sun M, et al. Preparation and characterization of intravenously injectable curcumin nanosuspension. Drug Deliv 2011; 18: 131-42.
13. Sun M, Gao Y, Pei Y, et al. Development of Nanosuspension Formulation for Oral Delivery of Quercetin. J Biomed Nanotechnol 2010; 6: 325-32.
14. Kobierski S, Ofori-Kwakye K, Muller RH, Keck CM. Resveratrol nanosuspensions: interaction of preservatives with nanocrystal production. Pharmazie 2011; 66: 942-7.
15. Zheng D, Wang Y, Zhang D, et al. In vitro antitumor activity of silybin nanosuspension in PC-3 cells. Cancer Lett 2011; 307: 158-64.
16. Shi Y, Porter W, Merdan T, Li LC. Recent advances in intravenous delivery of poorly water-soluble compounds. Expert Opin Drug Deliv 2009; 6: 1261-82.
17. Wong J, Brugger A, Khare A, et al. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev 2008; 60: 939-54.
18. Noyes WW. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897; 19: 930-4.
19. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 2008; 36: 43-8.
20. Buckton GAEB. The relationship between particle size and solubility. Int J Pharm 1992; 82: R7-10.
21. Muller KP. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int J Pharm 1998; 160: 229-37.
22. Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 2004; 284: 109-22.
23. Merle L. Dundon EMJ. The solubility and surface energy of calcium sulfate. J Am Chem Soc 1923; 45: 2479-85.
24. Dodiya SS, Chavhan SS, Sawant KK, Korde AG. Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies. J Microencapsul 2011; 28: 515-27.
25. Salem HF. Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats. Int J Nanomedicine 2010; 5: 943-54.
26. Chiang PC, Ran Y, Chou KJ, Cui Y, Wong H. Investigation of utilization of nanosuspension formulation to enhance exposure of 1,3-dicyclohexylurea in rats: Preparation for PK/PD study via subcutaneous route of nanosuspension drug delivery. Nanoscale Res Lett 2011; 6: 413.
27. Detroja C, Chavhan S, Sawant K. Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study. Sci Pharm 2011; 79: 635-51.
28. Van Eerdenbrugh B, Vermant J, Martens JA, et al. Solubility Increases Associated with Crystalline Drug Nanoparticles: Methodologies and Significance. Mol Pharm 2010; 7: 1858-70.
29. Junemann D, Dressman J. Analytical methods for dissolution testing of nanosized drugs. J Pharm Pharmacol 2012; 64: 931-43.
30. Radtke M. Nanopure: pure drug nanoparticles for the formulation of poorly soluble drugs. New Drugs 2001; 3: 62-8.
31. Müller JMaRH. Drug Nanocrystals-The Universal Formulation Approach for Poorly Soluble Drugs. In: Deepak Thassu MD, Yashwant Pathak, eds., Nanoparticulate Drug Delivery Systems. Taylor & Francis Group: New York, LLC 2006; pp: 71-88.
32. Kakran M, Shegokar R, Sahoo NG, et al. Fabrication of quercetin nanocrystals: comparison of different methods. Eur J Pharm Biopharm 2012; 80: 113-21.
33. Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 2008; 3: 295-309.
34. Pardeike J, Muller RH. Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18. Int J Pharm 2010; 391: 322-9.
35. Verma S, Huey BD, Burgess DJ. Scanning probe microscopy method for nanosuspension stabilizer selection. Langmuir 2009; 25: 12481-7.
36. Moschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm 2012.
37. Juhnke M, Berghausen J, Timpe C. Accelerated Formulation Development for Nanomilled Active Pharmaceutical Ingredients Using a Screening Approach. Chem Eng Technol 2010; 33: 1412-8.
38. Kim JH, Jang SW, Han SD, Hwang HD, Choi HG. Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods. Pharmazie 2011; 66: 491-5.
39. R. H Müller CJ, O Kayser. Nanosuspensions as particulatedrugformulations in therapy: Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001; 47: 3-19.
40. Juhnke M, Martin D, John E. Generation of wear during the production of drug nanosuspensions by wet media milling. Eur J Pharm Biopharm 2012; 81: 214-22.
41. Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm 2011; 409: 260-8.
42. Al Shaal L, Muller RH, Shegokar R. smartCrystal combination technology--scale up from lab to pilot scale and long term stability. Pharmazie 2010; 65: 877-84.
43. Nakarani M, Patel P, Patel J, Murthy RS, Vaghani SS. Cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation. Sci Pharm 2010; 78: 345-61.
44. Singh SK, Srinivasan KK, Gowthamarajan K, et al. Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. Eur J Pharm Biopharm 2011; 78: 441-6.
45. Knieke C, Steinborn C, Romeis S, et al. Nanoparticle Production with Stirred-Media Mills: Opportunities and Limits. Chem Eng Technol 2010; 33: 1401-11.
46. He MZ, Forssberg E. Influence of slurry rheology on stirred media milling of quartzite. Int J Miner Process 2007; 84: 240-51.
47. Breitung-Faes S, Kwade A. Produktgestaltung bei der Nanozerkleinerung durch Einsatz kleinster Mahlkörper. Chem-ingtech 2009; 81: 767-74.
48. Bernhardt ER, K Husemann. The influence of suspension properties on ultra-fine grinding in stirred ball mills. Powder Technol 1999; 105: 357-61.
49. Robert H. Davis J-M, Sa EJH. The elastohydrodynamic collision of two spheres. J Fluid Mech 1986; 163: 479-97
50. Knieke C, Sommer M, Peukert W. Identifying the apparent and true grinding limit. Powder Technol 2009; 195: 25-30.
51. Li LC, Tian Y. Zeta potential. In: J S, eds., Encyclopedia of pharmaceutical technology. Informa Health USA Inc.: New York 270 Madison. Avenue, New York, NY 10016 2007.
52. Kawakami K. Reversibility of enantiotropically related polymorphic transformations from a practical viewpoint: thermal analysis of kinetically reversible/irreversible polymorphic transformations. J Pharm Sci 2007; 96: 982-9.
53. Sharma P, Zujovic ZD, Bowmaker GA, et al. Evaluation of a crystalline nanosuspension: polymorphism, process induced transformation and in vivo studies. Int J Pharm 2011; 408: 138-51.
54. Basa S, Muniyappan T, Karatgi P, Prabhu R, Pillai R. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev Ind Pharm 2008; 34: 1209-18.
55. Thakkar HP, Patel BV, Thakkar SP. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement. J Pharm Bioallied Sci 2011; 3: 426-34.
56. Sun W, Mao S, Shi Y, Li LC, Fang L. Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. J Pharm Sci 2011; 100: 3365-73.
57. Sun W, Tian W, Zhang Y, et al. Effect of novel stabilizers-cationic polymers on the particle size and physical stability of poorly soluble drug nanocrystals. Nanomedicine 2012; 8: 460-7.
58. Gao L, Liu G, Wang X, et al. Preparation of a chemically stable quercetin formulation using nanosuspension technology. Int J Pharm 2011; 404: 231-7.
59. Moribe K, Wanawongthai C, Shudo J, Higashi K, Yamamoto K. Morphology and surface States of colloidal probucol nanoparticles evaluated by atomic force microscopy. Chem Pharm Bull (Tokyo) 2008; 56: 878-80.
60. Wang Y, Liu Z, Zhang D, et al. Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension. Colloids Surf B Biointerfaces 2011; 83: 189-97.
61. Van Eerdenbrugh B, Vermant J, Martens JA, et al. A screening study of surface stabilization during the production of drug nanocrystals. J Pharm Sci 2009; 98: 2091-103.
62. Liu G, Zhang D, Jiao Y, et al. Comparison of different methods for preparation of a stable riccardin D formulation via nanotechnology. Int J Pharm 2012; 422: 516-22.
63. Li W, Yang Y, Tian Y, et al. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. Int J Pharm 2011; 408: 157-62.
64. Lai F, Sinico C, Ennas G, et al. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour. Int J Pharm 2009; 373: 124-32.
65. Ali HS, York P, Ali AM, Blagden N. Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling. J Control Release 2011; 149: 175-81.
66. Steckel H, Rasenack N, Villax P, Muller BW. In vitro characterization of jet-milled and in-situ-micronized fluticasone-17-propionate. Int J Pharm 2003; 258: 65-75.
67. Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev 2011; 63: 456-69.
68. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004; 3: 785-96.
69. Ain-Ai A, Gupta PK. Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers on the physical stability of high drug loading nanosuspensions of a poorly soluble compound. Int J Pharm 2008; 351: 282-8.
70. Lindfors L, Skantze P, Skantze U, et al. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir 2006; 22: 906-10.
71. Carstensen JT. Solubility. In: Advanced pharmaceutical solids. Marcel Dekker 2001; pp. 27-50.
72. Tadros TF. Surfactans in pharmaceutical formulations. In: Applied Surfactants:Principles and Applications. Wiley-VCH 2005; pp. 433-502.
73. McClements DJ. Emulsion stability. In: David Julian McClements Ed. Food Emulsions: Principles, Practices, and Techniques, second edition. CRC Press 2004; pp. 185-234.
74. Pu X, Sun J, Wang Y, et al. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int J Pharm 2009; 379: 167-73.
75. He W, Lu Y, Qi J, et al. Food proteins as novel nanosuspension stabilizers for poorly water-soluble drugs. Int J Pharm 2012.
76. Yu. S. Lipatov GVD, V. N. Chornaya. Todosiichuk Change of molecular weight distribution of polymers by adsorption from binary and ternary solutions. Colloid Surface A 2008; 326: 53-60.
77. Abdelbary AA, Li X, El-Nabarawi M, Elassasy A, Jasti B. Effect of fixed aqueous layer thickness of polymeric stabilizers on zeta potential and stability of aripiprazole nanosuspensions. Pharm Dev Technol 2012.
78. Kim C. Surface chemistry and colloids. In: Advanced pharmaceutics: physico-chemical principles. CRC Press 2004; pp. 193-256.
79. Reddy MTH, Na IK. General principles of suspensions. In: A.K. Kulshreshtha ONS, G.M. Wall eds., Pharmaceutical suspensions: from formulation development to Manufacturing Springer 2009; pp. 39-66.
80. Chingunpitak J, Puttipipatkhachorn S, Chavalitshewinkoon-Petmitr P, et al. Formation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by cogrinding method. Drug Dev Ind Pharm 2008; 34: 314-22.
81. M.J. Rosen. Dispersion and aggregation of solid in liquid medium by surfactants. In: Surfacta nts and Interfa cial Phenomena. John Wiley & Sons 2004; pp. 337-62.
82. Roscigno P, Asaro F, Pellizer G, Ortona O, Paduano L. Complex formation between poly(vinylpyrrolidone) and sodium decyl sulfate studied through NMR. Langmuir 2003; 19: 9638-44.
83. Fang Li G-ZL, Gui-Ying Xu, Han-Qing Wang and Min Wang. Studies on the interactions between anionic surfactants and polyvinylpyrrolidone: Surface tension measurement, 13C NMR and ESR. Colloid Polym Sci 1998; 276: 1-10.
84. Ralf Nörenberg JK, Dieter Horn Study of the Interactions between Poly(vinyl pyrrolidone) and Sodium Dodecyl Sulfate by Fluorescence Correlation Spectroscopy Angew Chem Int Edit 1999; 38: 1626-9.
85. Dipankar Sukul SKP, Debabrata Mandal, Sobhan Sen, and Kankan Bhattacharyya Excited State Proton Transfer as a Probe for Polymer-Surfactant Interaction. J Phys Chem B 2000; 104 (26): 6128-32.
86. Cattoz B, Cosgrove T, Crossman M, Prescott SW. Surfactantmediated desorption of polymer from the nanoparticle interface. Langmuir 2012; 28: 2485-92.
87. Pongpeerapat A, Wanawongthai C, Tozuka Y, Moribe K, Yamamoto K. Formation mechanism of colloidal nanoparticles obtained from probucol/PVP/SDS ternary ground mixture. Int J Pharm 2008; 352: 309-16.
88. Verma S, Gokhale R, Burgess DJ. A comparative study of topdown and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm 2009; 380: 216-22.
89. Monteiro A, Afolabi A, Bilgili E. Continuous production of drug nanoparticle suspensions via wet stirred media milling: a fresh look at the Rehbinder effect. Drug Dev Ind Pharm 2012; 39: 266-83.
90. Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem 2004; 11: 413-24.
91. Zhang JQ, Liu J, Li XL, Jasti BR. Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv 2007; 14: 381-7.
92. Johnson BM, Charman WN, Porter CJH. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on Pglycoprotein efflux and enterocyte-based metabolism in excised rat intestine. Aaps Pharmsci 2002; 4: E 40.
93. Bernkop-Schnurch A, Dunnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm 2012; 81: 463-9.
94. Wang Y, Li X, Wang L, et al. Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. Int J Nanomedicine 2011; 6: 1497-507.
95. Cerdeira AM, Mazzotti M, Gander B. Miconazole nanosuspensions: Influence of formulation variables on particle size reduction and physical stability. Int J Pharm 2010; 396: 210-8.
96. Trache A, Meininger GA. Atomic force microscopy (AFM). Curr Protoc Microbiol 2008; Chapter 2: Unit 2C
97. Liu S, Wang Y. Application of AFM in microbiology: a review. Scanning 2010; 32: 61-73.
98. Deng J, Huang L, Liu F. Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm 2010; 390: 242-9.
99. Pilcer G, Vanderbist F, Amighi K. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. Int J Pharm 2009; 365: 162-9.
100. Mishra PR, Al Shaal L, Muller RH, Keck CM. Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int J Pharm 2009; 371: 182-9.
101. Müller RH. Zetapotential und Partikelladung-Kurze Theorie, praktische Messdurchfuhrung, Dateninterpretation. Stuttgart: Wissenschftliche. 1996.
102. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm 2005; 299: 167-77.
103. Shegokar R, Muller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 2010; 399: 129-39.
104. Singare DS, Marella S, Gowthamrajan K, et al. Optimization of formulation and process variable of nanosuspension: An industrial perspective. Int J Pharm 2010; 402: 213-20.
105. Peltonen L, Valo H, Kolakovic R, Laaksonen T, Hirvonen J. Electrospraying, spray drying and related techniques for production and formulation of drug nanoparticles. Expert Opin Drug Deliv 2010; 7: 705-19.
106. Mastersa K. Scale-up of spray dryers. Dry Technol 1994; 12: 235-57.
107. Niwa T, Miura S, Danjo K. Design of dry nanosuspension with highly spontaneous dispersible characteristics to develop solubilized formulation for poorly water-soluble drugs. Pharm Res 2011; 28: 2339-49.
108. Gao Y, Qian S, Zhang J. Physicochemical and pharmacokinetic characterization of a spray-dried cefpodoxime proxetil nanosuspension. Chem Pharm Bull (Tokyo) 2010; 58: 912-7.
109. Cal K, Sollohub K. Spray drying technique. I: Hardware and process parameters. J Pharm Sci 2010; 99: 575-86.
110. Snyder HE. Pharmaceutical spray drying: solid-dose process technology platform for the 21st century. Ther Deliv 2012; 3: 901-12.
111. Wahlberg JSLaM. Spray drying for processing of nanomaterials. J Phys Conf Ser 2009; 170.
112. Pamujula S, Graves RA, Freeman T, et al. Oral delivery of spray dried PLGA/amifostine nanoparticles. J Pharm Pharmacol 2004; 56: 1119-25.
113. Masters K. Applications of spray drying. In: Spray Drying Handbook(3rd Edition). Halsted Press New York 1979; pp. 481-516
114. Freitas S, Merkle HP, Gander B. Ultrasonic atomisation into reduced pressure atmosphere--envisaging aseptic spray-drying for microencapsulation. J Control Release 2004; 95: 185-95.
115. Elversson J, Millqvist-Fureby A. Particle size and density in spray drying-effects of carbohydrate properties. J Pharm Sci 2005; 94: 2049-60.
116. Corrigan DO, Corrigan OI, Healy AM. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. Int J Pharm 2006; 322: 22-30.
117. Mosen K, Backstrom K, Thalberg K, et al. Particle formation and capture during spray drying of inhalable particles. Pharm Dev Technol 2004; 9: 409-17.
118. Iskandar F, Gradon L, Okuyama K. Control of the morphology of nanostructured particles prepared by the spray drying of a nanoparticle sol. J Colloid Interface Sci 2003; 265: 296-303.
119. Sen D, Spalla O, Tache O, Haltebourg P, Thill A. Slow drying of a spray of nanoparticles dispersion. In situ SAXS investigation. Langmuir 2007; 23: 4296-302.
120. Chaubal MV, Popescu C. Conversion of nanosuspensions into dry powders by spray drying: a case study. Pharm Res 2008; 25: 2302-8.
121. Dolenc A, Govedarica B, Dreu R, et al. Nanosized particles of orlistat with enhanced in vitro dissolution rate and lipase inhibition. Int J Pharm 2010; 396: 149-55.
122. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 2006; 58: 1688-713.
123. Sigfridsson K, Lundqvist AJ, Strimfors M. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev Ind Pharm 2009; 35: 1479-86.
124. Abdelwahed W, Degobert G, Fessi H. Investigation of nanocapsules stabilization by amorphous excipients during freezedrying and storage. Eur J Pharm Biopharm 2006; 63: 87-94.
125. Dulieu C, Bazile D. Influence of lipid nanocapsules composition on their aptness to freeze-drying. Pharm Res 2005; 22: 285-92.
126. Mauludin R, Muller RH, Keck CM. Development of an oral rutin nanocrystal formulation. Int J Pharm 2009; 370: 202-9.
127. Lee MK, Kim MY, Kim S, Lee J. Cryoprotectants for freeze drying of drug nano-suspensions: effect of freezing rate. J Pharm Sci 2009; 98: 4808-17.
128. Lee J, Cheng Y. Critical freezing rate in freeze drying nanocrystal dispersions. J Control Release 2006; 111: 185-92.
129. Chung NO, Lee MK, Lee J. Mechanism of freeze-drying drug nanosuspensions. Int J Pharm 2012; 437: 42-50.
130. Date PV, Samad A, Devarajan PV. Freeze thaw: a simple approach for prediction of optimal cryoprotectant for freeze drying. AAPS PharmSciTech 2010; 11: 304-13.
131. Abdelwahed W, Degobert G, Fessi H. A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): formulation and process optimization. Int J Pharm 2006; 309: 178-88.
132. Beirowski J, Inghelbrecht S, Arien A, Gieseler H. Freeze drying of nanosuspensions, 2: the role of the critical formulation temperature on stability of drug nanosuspensions and its practical implication on process design. J Pharm Sci 2011; 100: 4471-81.
133. L.M. Crowe DSR, J.H. Crowe. Is trehalose special for preserving dry biomaterials? Biophysical journal 1996; 71: 2087-93.
134. Moschwitzer JP, Muller RH. Factors influencing the release kinetics of drug nanocrystal-loaded pellet formulations. Drug Dev Ind Pharm 2012; 39: 762-69.
135. Kayaert P, Anne M, Van den Mooter G. Bead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in-vitro release from sugar beads. J Pharm Pharmacol 2011; 63: 1446-53.
136. Beirowski J, Inghelbrecht S, Arien A, Gieseler H. Freeze-drying of nanosuspensions, part 3: investigation of factors compromising storage stability of highly concentrated drug nanosuspensions. J Pharm Sci 2012; 101: 354-62.
137. Liu Y, Xie P, Zhang D, Zhang Q. A mini review of nanosuspensions development. J Drug Target 2012; 20: 209-23.
138. Layre AM, Couvreur P, Richard J, et al. Freeze-drying of composite core-shell nanoparticles. Drug Dev Ind Pharm 2006; 32: 839-46.
139. Beirowski J, Inghelbrecht S, Arien A, Gieseler H. Freeze-drying of nanosuspensions, 1: freezing rate versus formulation design as critical factors to preserve the original particle size distribution. J Pharm Sci 2011; 100: 1958-68.
140. Persson EM, Nordgren A, Forsell P, et al. Improved understanding of the effect of food on drug absorption and bioavailability for lipophilic compounds using an intestinal pig perfusion model. Eur J Pharm Sci 2008; 34: 22-9.
141. Lenhardt T, Vergnault G, Grenier P, Scherer D, Langguth P. Evaluation of nanosuspensions for absorption enhancement of poorly soluble drugs: in vitro transport studies across intestinal epithelial monolayers. AAPS J 2008; 10: 435-8.
142. Li X, Gu L, Xu Y, Wang Y. Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. Drug Dev Ind Pharm 2009; 35: 827-33.
143. Dongowski G, Fritzsch B, Giessler J, et al. The influence of bile salts and mixed micelles on the pharmacokinetics of quinine in rabbits. Eur J Pharm Biopharm 2005; 60: 147-51.
144. Hecq J, Deleers M, Fanara D, et al. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm 2006; 64: 360-8.
145. Sigfridsson K, Lundqvist AJ, Strimfors M. Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development. Drug Dev Ind Pharm 2011; 37: 243-51.
146. Sigfridsson K, Lundqvist A, Strimfors M. Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor--the importance of gastrointestinal pH and solubility for the in vivo exposure. Drug Dev Ind Pharm 2011; 37: 1036-42.
147. Muller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm 2002; 237: 151-61.
148. Rabinow B, Kipp J, Papadopoulos P, et al. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm 2007; 339: 251-60.
149. Ben Zirar S, Astier A, Muchow M, Gibaud S. Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. Eur J Pharm Biopharm 2008; 70: 649-56.
150. Gao L, Zhang D, Chen M, et al. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm 2008; 355: 321-7.
151. Date AA, Joshi MD, Patravale VB. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 2007; 59: 505-21.
152. Lou H, Gao L, Wei X, et al. Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice. Colloids Surf B Biointerfaces 2011; 87: 319-25.
153. Du S, Zhu L, Du B, et al. Pharmacokinetic evaluation and antitumor activity of 2-methoxyestradiol nanosuspension. Drug Dev Ind Pharm 2012; 38: 431-8.
154. Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012; 33: 4889-906.
155. Liu Y, Huang L, Liu F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm 2010; 7: 863-9.
156. Mo R, Jin X, Li N, et al. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles. Biomaterials 2011; 32: 4609-20.
157. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res 2009; 26: 1197-216.
158. Gupta H, Aqil M, Khar RK, et al. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomed Nanotechnol 2010; 6: 324-33.
159. Araujo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine 2009; 5: 394-401.
160. Kassem MA, Rahman AAA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 2007; 340: 126-33.
161. Wu XG, Xin M, Yang LN, Shi WY. The biological characteristics and pharmacodynamics of a mycophenolate mofetil nanosuspension ophthalmic delivery system in rabbits. J Pharm Sci 2010; 100: 1350-61.
162. Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. Cationic vectors in ocular drug delivery. J Drug Target 2004; 12: 623-33.
163. Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm 2005; 290: 155-9.
164. de Salamanca AE, Diebold Y, Calonge M, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: Toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci 2006; 47: 1416-25.
165. Basaran E, Yazan Y. Ocular application of chitosan. Expert Opin Drug Deliv 2012; 9: 701-12.
166. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005; 172: 1487-90.
167. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003; 21: 1184-91.
168. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005; 85: 227-34.
169. Dailey LA, Schmehl T, Gessler T, et al. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Control Release 2003; 86: 131-44.
170. Finlay WH, Gehmlich MG. Inertial sizing of aerosol inhaled from two dry powder inhalers with realistic breath patterns versus constant flow rates. Int J Pharm 2000; 210: 83-95.
171. Hadinoto K, Phanapavudhikul P, Kewu Z, Tan RB. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids. Int J Pharm 2007; 333: 187-98.
172. Rao S, Song Y, Peddie F, Evans AM. Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs. Int J Nanomedicine 2011; 6: 1245-51.
173. Tanaka Y, Inkyo M, Yumoto R, et al. Nanoparticulation of poorly water soluble drugs using a wet-mill process and physicochemical properties of the nanopowders. Chem Pharm Bull (Tokyo) 2009; 57: 1050-7.
174. Mauludin R, Muller RH, Keck CM. Kinetic solubility and dissolution velocity of rutin nanocrystals. Eur J Pharm Sci 2009; 36: 502-10.
175. Kayser O, Olbrich C, Yardley V, Kiderlen AF, Croft SL. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003; 254: 73-5.
176. Wang Y, Zhang D, Liu Z, et al. In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnology 2010; 21: 155104.
177. Moschwitzer J, Achleitner G, Pomper H, Muller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm 2004; 58: 615-9.
178. Xiong R, Lu W, Li J, et al. Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int J Pharm 2008; 350: 338-43.
179. Ganta S, Paxton JW, Baguley BC, Garg S. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm 2009; 367: 179-86.
180. Jacobs C, Kayser O, Muller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm 2000; 196: 161-4.
181. Gao Y, Li Z, Sun M, et al. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev Ind Pharm 2010; 36: 1225-34.
182. Yang JZ, Young AL, Chiang PC, Thurston A, Pretzer DK. Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies. J Pharm Sci 2008; 97: 4869-78.
183. Hernandez-Trejo N, Kayser O, Steckel H, Muller RH. Characterization of nebulized buparvaquone nanosuspensions--effect of nebulization technology. J Drug Target 2005; 13: 499-507.
184. Jacobs C, Muller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 2002; 19: 189-94.